

References

- Abdel-Gafar, Y.; Sleem, H.; Tawfik, M. et al. (2002):** Percutaneous ethanol injection in large size and multiple HCC: two years follow-up in 165 patients. *Med. J. Cairo University*; 70(4), suppl. II, December
- Abdel-Wahab, M.; El-Enein, A.A.; Abou-Zeid, M.; et al. (2000):** Hepatocellular carcinoma in Mansoura-Egypt: experience of 386 patients at a single centre. *Hepatogastroenterology*; 47: 663-8.
- Abdel-Wahab, M.; El-Ghawalby, N.; Mostafa, M.; et al. (2007):** Epidemiology of hepatocellular carcinoma in lower Egypt, Mansoura gastroenterology centre. *Hepato-Gastroenterology*; 54: 157-162.
- Abe K, Edamoto Y, Park YN, , Tani M, Thung SN (1998).** In situ detection of hepatitis B, C, and G virus nucleic acids in human hepatocellular carcinoma tissues from different geographic regions.
- Adami, H.O.; Chow, W.H.; Nyren, O.; et al. (1996):** Excess risk of primary liver cancer in patients with diabetes mellitus. *J Nat Cancer Inst*; 1472-1477.
- Ahrar, K. and Gupta, S. (2003):** Hepatic artery embolization for hepatocellular carcinoma: technique, patient selection, and outcomes. *Surg Oncol Clin N Am*; 12: 105-126.
- Akere, A. and Otegbayo, J.A. (2007):** Evaluation of the pattern and prognostic implications of anti-p53 in hepatocellular carcinoma. *Singapore Med J*; 48 (1): 41.

- Akiba, S.J.; Choi, I.K.; Park, K.H.; Yoon, S.Y.; et al. (2001):** Expression and function of interleukin-8 in human hepatocellular carcinoma. *Int J Oncol*; 18: 257-264.
- Akriviadis, E.A.; Llovet, J.M.; Efremidis, S.C.; et al. (1998):** Hepatocellular carcinoma. *British J of Surgery*; 85: 1319-1331.
- Anthony, P.P. (2001):** Hepatocellular carcinoma: an overview. *Histopathology*; 39: 109-118.
- Anwar, W.A.; Khaled, H.M.; Amra, H.A.; et al. (2008):** Changing pattern of hepatocellular carcinoma (HCC) and its risk factors in Egypt: Possibilities for prevention. *Mutat Reas; (Epub ahead of print). (Abstract)*.
- Aoki, K.; Okazaki, N.; Okada, S.; et al. (1994):** Radiotherapy for hepatocellular carcinoma: clinicopathological study of seven autopsy cases. *Hepatogastroenterology*; 41: 427-431.
- Aoun, E. and Taher, A. (2002):** The clinical implications of angiogenesis in the treatment of cancer. *J Med Liban*; 50: 32-38.
- Araki, Y.; Hukano, M.; Urabe, M.; et al. (2004):** Hepatocellular carcinoma treated by percutaneous hot saline injection. *Oncology reports*; 12: 569-571.
- Ashorn M, Pitkanen S, Salo MK, Heikinheimo M. (2006)** Current strategies for the treatment of hereditary tyrosinemia type I. *Paediatr Drugs*; 8: 47-54
- Badawi, A.F. and Michael, M.S. (1999):** Risk factors for hepatocellular carcinoma in Egypt: The role of hepatitis

- B viral infection and schistosomiasis. *Anticancer research*; 19: 4563-4568.
- Baron, R.L.; Oliver, J.H.; Dodd, G.D.; et al. (1996):** Hepatocellular carcinoma: evaluation with biphasic, contrast-enhanced, helical CT. *Radiology*; 199: 505-511.
- Bartolozzi, C.; Lencioni, R.; Caramella, D.; et al. (1995):** Treatment of large HCC: transcatheter arterial chemoembolization combined with percutaneous ethanol injection versus repeated transcatheter arterial chemoembolization. *Radiology*; 197(3): 812-818.
- Bassily S, Hyams KC, el-Masry NA, Hassan NF, Watts DM (1992).** Hepatitis C virus infection and hepatosplenic schistosomiasis. *Scand J Infect Dis* 1992; 24: 687-688
- Bataller, R. and Brenner, D.A. (2005):** Liver fibrosis. *J Clin Invest*; 115: 209-218.
- Baudina , S . (1987) :** The active substances of mistetae
Pharmacological properties and therapeutic application
Annals des. Sciences Naturals Botanique , 13:45 – 72 .
- Becker, G.; Allgaier, H.P.; Olschewski, M.; et al. (2007):** Long acting octreotide vs placebo for treatment of advanced HCC: a randomized controlled double-blind study. *Herpetology*; 45: 9-15.
- Befeler, A.S. and Di Bisceglie, A.M. (2002).** Hepatocellular carcinoma: diagnosis and treatment. *Gastroenterology*; 122: 1609-1619.
- Benvegna, L.; Noventa, F.; Bernardinello, E.; et al. (2001):** Evidence for an association between the aetiology of

cirrhosis and pattern of HCC development. *Gut*; 48:110-115.

Beppu, T.; Ishiko, T.; Doi, K.; et al. (2001): A promising new treatment strategy for advanced hepatocellular carcinoma –“multi-ablation therapy” consisting of radiofrequency ablation(RFA) microwave coagulation (MCT), and ethanol injection therapy (EIT). *Gan To Kagaku Ryoho*; 28 (11): 1583-1586.

Bhattacharya, S.; Davidson, B.; Dhillon, A.P.; et al. (1995): Blood supply of early hepatocellular carcinoma. *Semin Liver Dis*; 15: 390-401.

Bhosale, P.; Szklaruk, J. and Silverman, P. M. (2006): Current staging of hepatocellular carcinoma: imaging implications. *Cancer Imaging*; 6: 83–94.

Bhosale, P.; Szklaruk, J. and Silverman, P. M. (2006): Current staging of hepatocellular carcinoma: imaging implications. *Cancer Imaging*; 6: 83–94.

Bilacki ES ., Ezenkwe AM., Burnt EM., et al . (2006) : Comperison of liver biopsy and non invasive Methods for deaqnesis of HCC. *Clin . Gastroenterology .,Hepatol.*, 4(3) : 361 – 68 .

Blum, H.E., (2005): Hepatocellular carcinoma: therapy and prevention. *World J of Gastroenterology*; 11(47): 7391-7400.

Boer, W.B.; Segal, A.; Frost, F.A.; et al. (1999): Cytodiagnosis of well differentiated hepatocellular carcinoma: can

indeterminate diagnosis be reduced *Cancer*; 87: 270-277.

Bolondi, L.; Sofia, S.; Siring, S. et al. (2001): Surveillance programme of cirrhotic patients for early diagnosis and treatment of hepatocellular carcinoma: a cost effectiveness analysis. *Gut*; 48: 251-259.

Bosch FX, Ribes J, Diaz M, Cleries R.(2004) Primary liver cancer worldwide incidence and trends. *Gastroenterology* 2004; 127: S5-S16

Brancatelli, G.; Baron, R.L.; Peterson, M.S.; et al. (2003): Helical CT screening for HCC in patients with cirrhosis: frequency and causes of false positive interpretation. *Am J Roenterol*; 180(4): 1007-1014.

Brechot C, Nalpas B, Feitelson MA. 1996 Interactions between alcohol and hepatitis viruses in the liver, *in Lab Med*; **16**: 273-287

Breedis, C. and Young, G. (1954): The blood supply of neoplasms in the liver. *Am J Pathol*; 30: 969-977.

Bruix, J., and Sherman, M. (2005): Management of hepatocellular carcinoma. *Hepatology*; 42(5): 1208-1236

Bruix, J.; Sherman, M.; Llovet, J.M.; et al. (2001): Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. *J Hepatol*; 35: 421-430.

Bruix, J.; Sherman, M.; Llovet, J.M.; et al. (2001): Clinical management of hepatocellular carcinoma. Conclusions

- of the Barcelona-2000 EASL conference. *J Hepatol*; 35: 421-430.
- Brunt, E.M.; Janney, C.G.; Di-Bisceglie, A.M.; et al. (1999):** Non-alcoholic steatohepatitis: a proposal for grading and staging of the histologic lesions. *Am J Gastroenterol*; 94: 2467-2474
- Bugianesi, E.; Leone, N.; Vanni, E.; et al. (2002):** Expanding the natural history of non-alcoholic steatohepatitis: From cryptogenic cirrhosis to hepatocellular carcinoma. *Gastroenterology*; 123: 134-140.
- But DYK, Lai CL, Yuen MF.** Natural history of hepatitis-related hepatocellular carcinoma. *World J Gastroenterol* 2008; 14:1652-1656.[CrossReOIMedline]
- But DYK, Lai CL, Yuen MF. (2008):** Natural history of hepatitis-related hepatocellular carcinoma. *World J Gastroenterol*; 14:1652-1656.[CrossReOIMedline]
- C. Frank, M.K. Mohamed, G.T. .; et al. (2000):** The role of parenteral antischistosomal therapy in the spread of hepatitis C in Egypt, *Lancet* 355 887–891
- Cacciola I, Pollicino T, Raimondo G. (1999):** Occult hepatitis B virus infection in patients with chronic hepatitis C liver disease. *N Engl J Med*; 341: 22-26
- Calle, E.E.; Rodriguez, C.; Thun, M.J.; et al. (2003):** Overweight, obesity and mortality from cancer in a prospectively studied cohort of US adults. *N Engl J Med*; 348: 1625-1638.

- Capurro, M.; Wanless, I.R.; Sherman, M.; et al. (2003):** Glypican-3: a novel serum and histochemical marker for hepatocellular carcinoma. *Gastroenterology*; 125: 89-97.
- Carr, B.I. (2004)** Hepatocellular carcinoma: current management and future trends. *Gastroenterology*; 127; S218-S224.
- Caturelli, E.; Solmi, L.; Anti, M.; et al. (2004):** Us-guided fine needle biopsy of early hepatocellular carcinoma complicating liver cirrhosis: a multicenter study. *Gut*; 53: 1356-1362
- Chang, M.H.; Chen, C.J.; Lai, M.S.; et al. (1997):** Universal hepatitis B vaccination in Taiwan and incidence of HCC in children. *N Engl J Med*; 336: 1855-1859.
- Charuruks, N.; Tangkuvanich, P.; Voravud, N. et al. (2001):** Clinical significance of p53 antigen and anti-p53 antibodies in the sera of hepatocellular carcinoma patients. *J. Gastroetnerol.*; 36: 830-836.
- Chedid, A.; Ryan L.M.; Dayal, Y.; et al. (1999):** Morphology and other pathologic factors of hepatocellular carcinoma. *Arch Pathol Lab Med*; 123: 524-528.
- Chen, C.J.; Yang, H.I.; Su, J.; (2006):** Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. *JAMA*; 295: 65-73.
- Chen, Min, Hui-Hong; -Shan; Li, Jin-Qing; Zheng, Yun; Guo, Rong-Ping; Liang Zhang, Ya-Qi; Lin, Xiao-Jun; Lau, Wan Y (2006).** "A Prospective Randomized Trial Comparing Percutaneous Local Ablative Therapy and

- Partial Hepatectomy for Small Hepatocellular Carcinoma". *Annals of Surgery* **243** (3): 321-8. doi:10.1097/01.sla.0000201480.65519.b8. PMID 16495695
- Chen, T.W.; Chu, C.M.; Yu, J.C.; Chen, D.C.; et al. (2007):** Comparison of clinical staging systems in predicting survival of hepatocellular carcinoma patients receiving major or minor hepatectomy. *EJSO*; 33: 480-487.
- Chen, X.P.; Zhao, H. and Zhao, X.P. (2002):** Alteration of AFP-mRNA level detected in blood circulation during liver resection for HCC and its significance. *World J Gastroenterology*; 8: 818-821.
- Chiang DY., Villanueva A., Hoshida Y., et al . (2008):** A novel molecular classification of HCV – related HCC based on integrative genom analysis (abstract) . Presented at 3rd meeting of europ . Assoc for the study of liver Milan Italy , April24
- Chiou, H.Y.; Hsueh, Y.M.; Liaw, K.F. et al. (1995):** Incidence of internal cancers and ingested inorganic arsenic: a seven-year follow-up study in Taiwan. *Cancer Res*; 55: 1296-1300.
- Chow, D.H.; Sinn, L.H.; Ng, K.K.; et al. (2006):** Radiofrequency ablation for hepatocellular carcinoma and metastatic liver tumours: A comparative study. *J. Surg. Oncol*; 94: 565-571.
- CLIP (Cancer of the Liver Italian Program) Investigators (1998):** A new prognostic system for hepatocellular carcinoma:

- A retrospective study of 435 patients. *Hepatology*; 28: 751-755.
- Collaborative Milts Project Team. (1997):** Oral contraceptives and liver cancer. *Contraception*; 56: 275-284
- Colli A., Fraquelli M., Casazza G., et al . (2006) :** Accuracy of US , Spiral CT. MRI ,and alpha in diagnosing HCC : a Sptemicrevierr. Am ., JGastroenterol., 10 (3) : 513 – 23 .
- Collier, J. and Sherman M. (1998):** Screening for hepatocellular carcinoma. *Hepatology*; 27: 273-278.
- Cordier, S.; Le, T.B.; Verger, T.Q.; et al. (1993):** Viral infections and chemical exposures as risk factors for hepatocellular carcinoma in Vietnam. *Int J. Cancer*; 55(2): 196-201
- Cormier J.N.; Thomas, K.T.; Chari, R.S.; et al. (2006):** Management of hepatocellular carcinoma. *J Gastrointestinal Surg*; 10: 761-780.
- Craig, J.R. (2003):** Tumours of the liver. In: *Hepatology: a textbook of liver disease*. Zakim, D. and Boyer, T.D. (eds), fourth edition, Saunders, Philadelphia, London, New York, St. Louis, Sydney, Toronto, p: 1355-1370.
- Crawford M . (1999) :** The liver and Biliary tract. In : *Pathologic basis of diseases* 6th edit. By Cotran et al .
- Cua IH, Hui JM, Bandara P .;et al. (2007):** Insulin resistance and liver injury in hepatitis C is not associated with virus-specific changes in adipocytokines. *Hepatology* 2007;46:66-73.[CrossRefJLMedline]

- Cui, R.; Wang, B.; Ding, H.; et al. (2002):** Usefulness of determining a protein induced by vitamin K absence in detection of hepatocellular carcinoma. *Chin Med J (Engl)*; 115: 42-45.
- Daniele B., Beneivenga A., Megna AS ., and tinessa V . (2004):** Alpha fetoprotein and US screening for HCC. *Gastroenterology*, 127 (5 suppl. I) S 108 – S 112
- Davila JA, Morgan RO.; et al. (2005):** Diabetes increases the risk of hepatocellular carcinoma in the United States: a population based case control study. *Gut* 2005; 54: 533-539
- Davis Gl. Jane Dempster .,RN., James. D et al (2008):** HCC management of an increasingly common problem . *Proc (Bayl Univ. red cent)* , 21(3) : 266 – 280.
- Decadt, B. and Siriwardena, A.K. (2004):** Radiofrequency ablation of liver tumours: Systemic review. *Lancet Oncol*; 5: 550-560.
- Dettmer, A.; Kirchhoff, T.; Gebel, M.; et al. (2006):** Combination of repeated single-session percutaneous ethanol injection and transarterial chemoembolization compared to related single-session percutaneous ethanol injection in patients with non-resectable hepatocellular carcinoma. *World J Gastroenterol*; 12: 3707-3715.
- Di Bisceglie, A.M. (2002):** Epidemiology and clinical presentation of hepatocellular carcinoma. *J. Vasc. Interv. Radiol.*; 13: s169-s171.

- Di Maio, M.; De Maio, E.; Perrone, F.; et al. (2002):** Hepatocellular carcinoma: systemic treatments. *J Clin Gastroenterol*; 35 (Suppl. 2): S109-S114.
- Di Stasi, D.; Sykes, J.; Wilkinson, A.; et al. (1997):** Percutaneous ethanol injection in the treatment of hepatocellular carcinoma. A multicenter survey of evaluation practices and complication rates. *Scand.J.Gastroenterol*; 32: 1168-1173.
- Ding, X.; Yang, L.Y.; Huang, G.W.; et al. (2005):** Role of AFP mRNA expression in peripheral blood as a predictor of postsurgical recurrence of hepatocellular carcinoma: a systemic review and meta-analysis. *World J Gastroenterology*; 11: 2656-2661.
- Donato F, Tagger A .; et al. (2002):** Alcohol and hepatocellular carcinoma: the effect of lifetime intake and hepatitis virus infections in men and women. *Am J Epidemiol*; 155: 323-331
- Donato F, Tagger A.; et al., (1997):** Hepatitis B and C virus infection, alcohol drinking, and hepatocellular carcinoma: a case-control study in Italy. Brescia HCC Study. *Hepatology*; 26: 579-584
- Dong, Z.Z.; Zou, L.; Yao, D.B.; et al. (2006):** Expression of hepatoma and circulating growth factor beta 1-mRNA and its clinical values in diagnosis of patients with liver cancer. *J. Gastroenterology Hepatol*; 21(S1):A172.
- Du X.L.; Ma, Q.J.; Wu, T.; Bao, G.Q.; et al. (2007):** Significance of alpha-fetoprotein mRNA level in hepatocellular

- carcinoma patients treated with radiofrequency ablation.
Hepatobiliary, Pancreat Dis int; 15: 172-175.
- El – Attar I., (2002) :** cancer Registration NCI in Egypt National Joint Cancer Conference, March.
- El – Serag, H. B. (2002) :** Hepatocellular carcinoma and hepatitis C in the United States. *Hepatology, 36 :74 – 83.*
- El – Zayadi A. (1989) :** Primary hepatic malignancies : Highlighting the Egyptian situation. Medical Forum , UK . Smith Kline and French Laboratories limited ; 33: 10- 15 .
- El Gohary A, Hassan A, .; et al. (1995):** High prevalence of hepatitis C virus among urban and rural population groups in Egypt. *Acta Trop 1995; 59: 155-161*
- El-Assal, O.N.; Yamanoi, A.; Soda, Y.; et al. (1997):** Proposal of invasiveness score to predict recurrence and survival after curative resection for hepatocellular carcinoma. *Surgery; 122: 571-577.*
- Elba, S.; Buongiorno, G.; Caruso, M.; et al. (2002):** Main characteristics of hepatocellular carcinoma and therapeutic approaches. *Curr Pharm; 8(11): 1007-1011*
- El-Far, M. A.; Atwa, M.A.; Yahya, R.S.; et al. (2006):** Evaluation of serum levels of p53 in hepatocellular carcinoma in Egypt. *Clin Chem Lab Med; 44: 653-656.*
- Elmberg M, Hultcrantz R.; et al. (2003):** Cancer risk in patients with hereditary hemochromatosis and in their first-degree relatives. *Gastroenterology 2003; 125:1733-1741*

- El-Meteini, M.; Fayez, A.; Fathy, N.; et al. (2005):** Liver related liver transplantation for hepatocellular carcinoma in Egypt. *Transplantation Proceedings*; 37: 3141-3143.
- El-Serag HB, Mason AC. (1999):** Rising incidence of hepatocellular carcinoma in the United States. *N Engl J Med*; 340: 745-750
- El-Serag, H.B. and Rudolph, K.L. (2007):** Hepatocellular carcinoma: Epidemiology and molecular carcinogenesis. *Gastroenterology*; 132: 2557-2576.
- El-Serag, H.B.; Mason, A.C.; Key, C. (2001):** Trends in survival of patients with hepatocellular carcinoma 1977 and 1996 in United States. *Hepatology*; 33:62-65.
- El-Shabrawi, A.; Bacher, H.; Cerwenka, G.; et al. (2002):** Is the information yielded by detection of circulating HCC cells in peripheral blood of clinical relevance *Eur. Surg.*; 34: 359-361.
- El-Zayadi, A.R.; Abaza, H.; Shawky, S.; et al. (2001):** Prevalence and epidemiology features of hepatocellular carcinoma in Egypt: a single centre experience.
- El-Zayadi, A.R.; Badran, H.M.; Barakat, E.M. et al. (2005):** Hepatocellular carcinoma in Egypt: a single center study over a decade. *World J of Gastroenterol.*; 11(33): 5193-5198
- Etzel, R.A. (2002):** Mycotoxins. *JAMA*; 287: 425-427.
- Evan, A.A.; Chen, G.; London, W.T.; et al. (2002):** Eight-year follow-up of the 90,000 person Haimen City cohort I: Hepatocellular carcinoma mortality, risk factors and

- gender differences. *Cancer Epidemiol Biomarkers Prev*; 11: 369-376.
- Fan, J.; Zhou, J.; Wu, Z.Q.; et al. (2005):** Efficacy of different treatment strategies for hepatocellular carcinoma with portal vein tumour thrombosis. *World J Gastroenterology*; 11(8): 1215-1219.
- Farrell, G.C. (2003):** Non-alcoholic steatohepatitis: what is it and why is important in the Asia-Pacific region *J Gastroenterol Hepatol*; 18: 124- 138.
- Fartoux, L.; Arrive, L.; Andreani, T.; et al. (2005):** Treatment of small hepatocellular carcinoma with acetic acid percutaneous injection: a single French centre experience. *Gastroenterol Clin Biol*; 29: 1213-1219.
- Fattovich G., Stroffolonin T. , Tagni I , and Donate F., (2004) :** HCC in cirrhosis incidence and risk factors. *Gastroenterolog.*, 127 (5 suppl.1) : S 335 – S50.
- Fattovich, G.; Giustina, G.; Schlm, S.W.; et al. (1995):** Occurrence of hepatocellular carcinoma and decompensation in western European patients for cirrhosis type B. the EUROHEP Study Group on hepatitis B virus and cirrhosis. *Hepatology*; 21: 77-82.
- Figa-Talamanca, I.; Mearelli, I. and Vlente, P. (1993):** Mortality in a cohort of pesticide applicators in an urban setting. *Int. J. Epidemiol.* 2; 4: 674-676
- Fong , Y. ; Venook , R. , and Lawrence , T . : (2002) :** Hepatocellur cancer: Clinical management . In : GIT Oncology : Principles and practice , edited by Kelsen ,

- D., ; Daly, J., Levin ; B, et al ., app., 579 – 600.
Philadelphia, Lippincott Williams and Wilkins.
- Fong, Y.; Fortner, J.; Sun, R.L.; et al. (1999):** Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: Analysis of 1001 consecutive cases. *Ann Surg*; 230: 309-318.
- Forner, A.; Vilana, R.; Ayuso, C.; et al. (2008):** Diagnosis of hepatic nodules 20 mm or smaller in cirrhosis: prospective validation of the non-invasive diagnostic criteria for hepatocellular carcinoma. *Hepatology*; 47: 97-104.
- Fracanzani AL, Conte D .; et al. (2001):** Increased cancer risk in a cohort of 230 patients with hereditary hemochromatosis in comparison to matched control patients with non-iron-related chronic liver disease. *Hepatology* 2001; 33: 647-651
- França, A.V.C.; Junior, J.E.; Lima, B.L.G. et al. (2004):** Diagnosis, staging and treatment of hepatocellular carcinoma. *Braz. J. Med. Biol. Res.*; 37(11): 1689-1705.
- Frank C, Mohamed MK, .; et al. (2005):** The role of parenteral antischistosomal therapy in the spread of hepatitis C virus in Egypt. *Lancet* 2000; 355: 887-891
- Frederick, L.; Greene, F.L.; Page, D.L.; et al. (2002):** AJCC cancer staging manual. 6th ed. *Chicago: Springer*; 131-144.
- Furuse, J.; Ishii, H.; Nagase, M.; et al. (2005):** Adverse hepatic events caused by radiotherapy for advanced

- hepatocellular carcinoma. *J of Gastroenterology and Hepatology*; 20: 1512-1528.
- Gad, A.; Tanka, E.; Matsumoto, A.; et al. (2005):** Ethnicity affect the diagnostic validity of alpha-fetoprotein in hepatoceular carcinoma. *Asia- Pacipic Journal of Clinical Oncology*; 1:64-70
- Gallo, C.; De Maio, E.; Di Maio, M.; et al. (2006):** Tamoxifen is not effective in good prognosis patients with hepatocellular carcinoma. *BMC Cancer*, 6.196: 1-5.
- Gauldie, J.; Richards, C.; Harnish, D.; et al. (1987):** Interferon beta 2/B-cell stimulatory factor type 2 shares identity with monocyte-derived hepatocyte-stimulaing factor and regulates the major acute phase protein response in liver cell. *Proc Natl Acad Sci USA*; 84: 7251-7255.
- Gianni, S.; Cechetto, A.; Altavilla, G.; et al.(2005):** Tumour staging, morphology and p53 overexpression concur in predicting survival in hepatocellular carcinoma. *J of Internal Medicine*; 257: 367-373.
- Giannitrapani, L.; Cervello, M.; Soresi, M.; et al. (2002):** Circulating IL-6 and sIL-6R in patients with hepatocellular carcinoma. *Ann N Y Acad Sci*; 963: 46-52.
- Gillams, A.R. (2005):** Image guided tumour ablation. *Cancer Imaging*; 5: 103-109.
- Gomaa AI, Khan SA, Toledano MB et al. (2008):** Epidemiology of hepatocellular carcinoma, risk factors and pathogenesis

- Gondolesi, G.E.; Florman, S.; Matsumoto, C.; et al. (2002):** Venous hemodynamics in living donor right lobe liver transplantation. *Liver Transpl*; 8: 809-813.
- Greenlee, R.T.; Hill-Harmon, M.B.; Murray, T.; et al. (2001):** Cancer statistics. *Cancer J Clin*; 51: 15-36.
- Greten, T.F.; Papendorf, F.; Bleck, J.S.; et al. (2005):** Survival rate in patients with hepatocellular carcinoma: a retrospective analysis of 389 patients. *British J of Cancer*; 92: 1862-1868.
- Grieco, A.; Pompili, M.; Caminiti, G. et al. (2005):** Prognostic factors for survival in patients with early intermediate hepatocellular carcinoma undergoing non-surgical therapy: comparison of Okuda, CLIP, and BCLC staging systems in a single Italian centre. *Gut*; 54: 411-418.
- Grieco, A.; Pompili, M.; Caminiti, G. et al. (2005):** Prognostic factors for survival in patients with early intermediate hepatocellular carcinoma undergoing non-surgical therapy: comparison of Okuda, CLIP, and BCLC staging systems in a single Italian centre. *Gut*; 54: 411-418.
- Guido, T.; Jacques, B., and Masatoshi, M. (2004):** Difference and similarities in the approach to HCC between Eastern and Western institutions. *Liver Transplantation*; 10(2) suppl. I, February.
- Gupta, S.; Bent, S. and Kohlwes, J. (2003):** Test characteristics of alpha-fetoprotein for detecting hepatocellular carcinoma

in patients with hepatitis C. A systematic review and critical analysis. *Ann. Intern. Med.*; 139: 46-50.

Hanazaki, K.,; Matsushita, A.; Nakagawa, K.; et al. (2005): Risk factors of long-term survival and recurrence after curative resection of hepatocellular carcinoma. *Hepatogastroenterology*; 52: 552-557.

Hannaford, P.C.; Kay, C.R.; Vessy, M.P.; et al. (1997): Combined oral contraceptive and liver disease. *Contraception*; 55: 145-151

Hassan, M.M.; Forme, A.; Patt, Y.Z. and El-Serag, H.B. (2002): Rising prevalence of hepatitis C virus infection among patients recently diagnosed with hepatocellular carcinoma in the United States. *J Clin Gastroenterol*; 35: 266-269

Hassan, M.M.; Zaghloul, A.S.; El-Serag H.B.; et al. (2001): The role of hepatitis C in hepatocellular carcinoma: a case control study among Egyptian patients. *J. Clin. Gastroenterology*; 33: 123-126

Heathcote, E.J. (2004): Prevention of hepatitis C virus-related hepatocellular carcinoma. *Gastroenterology*; 127: S294-S302.

Heintegs, T. and Wands J,R. (1997): Hepatitis C virus: epidemiology and transmission. *Hepatology*; 26: 521-526.

Hemming, A.W.; Scudamore, C.H.; Shackleton, C.R.; et al. (1992): Indocyanine green clearance as a predictor of

successful hepatic resection in cirrhotic patients. *Am J Surg*; 163: 515-518.

Hifnawy, M.S.; Mangoud, A.M.; Eissa, M.H.; et al. (2004): The role of AFB1-contaminated food materials and HCV in developing hepatocellular carcinoma in Al-Sharkia governorate: Egypt. *J Egypt Soc Parasitol*; 34: 479-488.

Hsu HC, Peng SY.; et al. (1994): Allelotype and loss of heterozygosity of p53 in primary and recurrent hepatocellular carcinomas. A study of 150 patients. *Cancer* 1994; 73: 42-47

Hsu, C.; Cheng, J. H. and Cheng, A.L. (2004): Recent advances in non-surgical treatment for advanced hepatocellular carcinoma. *J. Formos, Med. Assoc.*; 103(7): 483-495.

Hung, C.H.; Lee, C.M.; Wang, J.H.; et al. (2005): Antiviral therapy after non-surgical tumour ablation in patients with hepatocellular carcinoma associated with hepatitis C virus. *J of Gastroenterology and Hepatolgy*; 20: 1553-1559.

Huo, T.I.; Huang, Y.H.; Wu, J.C.; et al. (2003): Comparison of percutaneous acetic acid injection and percutaneous ethanol injection for hepatocellular carcinoma in cirrhotic patients: a prospective study. *Scand. J Gastroenterol*; 38: 770-778.

Huo, T.I.; Lin, H.C.; Hsia, C.Y.; et al. (2007): The Model for End-Stage Liver Disease based cancer staging systems are better prognostic models for hepatocellular carcinoma:

- a prospective survey. *Am J Gastroenterol*; 102: 1920-1930.
- Hussain, S.A.; Ferry, D.R.; El-Gazzaz, G.; et al. (2001):** Hepatocellular carcinoma. *Annals of Oncology*; 12: 161-172.
- IARC (The International Agency for Research on Cancer) Monographs, (1987):** Overall evaluations of carcinogenicity: An updating of IARC monographs; vol 1-42, supplement 7. Lyon: IARC press.
- IARC, (1991):** Occupational exposure in spraying and application of insecticides. *Mongraphs*; 53: 45
- Ijichi, M.; Takayama, T.; Matsumura, M.; et al. (2002):** Alpha-fetoprotein mRNA in the circulation as a predictor of postsurgical recurrence of hepatocellular carcinoma: a prospective study. *Hepatology*; 35: 853-860.
- Ikeda, M.; Okuda, S.; Ueno, H.; et al. (2001):** Radiofrequency ablation and percutaneous ethanol injection in patients with small hepatocellular carcinoma: a comparative study. *Jpn J Clin Oncol*; 31(7): 322326
- Inas Elattar, (2003):** Website of the National Cancer Institute, Egypt: <http://www.nci.edu.eg>
- Inoue, M.; Yoshimi, I.; Sobue, T. and Tsugane, S. (2005):** Influence of coffee drinking on subsequent risk of hepatocellular carcinoma: a prospective study in Japan. *J Nati Cancer Inst*; 97: 293-300.
- Ishizuka, H.; Nakayama, T.; Matsuoka, S.; et al. (1999):** Prediction of the development of hepatocellular carcinoma in

- patients with liver cirrhosis by the serial determination of serum alpha-L-fucosidase activity. *Intern Med*; 38: 927-931.
- Izuno, K.; Fujiyama, S.; Yamasaki, K.; et al. (1995):** Early detection of hepatocellular carcinoma associated with cirrhosis by combined assay of des-gamma-carboxy prothrombin and alpha-fetoprotein: a prospective study. *Hepatogastroenterology*; 42: 387-393.
- Jamagin , W.R.; Gonen , M. ; Fong , Y. ; et al . (2002) :** Improvement in preoperative outcome after hepatic resection. Analysis of 1803 Consecutive cases over the past decade. *Ann . Surg .*, 236 : 397 – 406 .
- Jansen, M.C.; Hillegersberg, R.; Chamuleau, R.A.; et al. (2005):** Outcome of regional and local ablative therapies for hepatocellular carcinoma: a collective review. *EJSO*; 31: 331-347.
- Jansen, M.C.; Hillegersberg, R.; Chamuleau, R.A.; et al. (2005):** Outcome of regional and local ablative therapies for hepatocellular carcinoma: a collective review. *EJSO*; 31: 331-347.
- K. Mostafa, (2004):** Epidemiology of HCV in Egypt, *Afro-Arab Liver J.* 3 (2) 41–52.
- Kane, R.A. (1993):** Ultrasound-guided hepatic cryotherapy for tumour ablation. *Semin Interv Radiol*; 10: 132-142.
- Kao, J.H.; Chen, P.J.; Lai. M.Y.; et al. (2002):** Genotype and clinical phenotypes of hepatitis B virus in patients with

- chronic hepatitis B virus infection. *J Clin Microbiol*; 40: 1207-1209.
- Kern PA, Ranganathan S, Li C, et al.(2001):** Adipose tissue tumor necrosis factor and interleukin-6 expression in human obesity and insulin resistance. *Am J Physiol Endocrinol Metab* 2001;280: E745-E751.[Abstract/Free FullText]
- Kew, M.C. (2002):** Epidemiology of hepatocellular carcinoma. *Toxicology*; 181- 182: 35-38.
- Kew, M.C. (2002):** Hepatic tumours and cysts. *Feldman: Sleisenger and Fordtran's G.I. and Liver disease*; 1577-1593.
- Khan SA, Taylor-Robinson SD, Toledano; et al. (2002):** Changing international trends in mortality rates for liver, biliary and pancreatic tumours. *J Hepatol* 2002; 37: 806-813
- Khein, V.V.; Mao, H.V.; Chinh, T.T.; et al. (2001):** Clinical evaluation of lentil lectin-reactive alpha-fetoprotein-L3 in histology-proven hepatocellular carcinoma. *Int J Biol Markers*; 16: 105-111.
- Kim, S. H.; Lim, H.K.; Choi, D., et al. (2006):** Percutaneous radiofrequency ablation of hepatocellular carcinoma: effect of histologic grade on therapeutic results. *AJR*; 186:S327-S333
- Kim, S.J.; Choi, I.K.; Park, K.H.; et al. (2004):** Serum vascular endothelial factor per platelet count in hepatocellular carcinoma: correlations with clinical parameter and survival. *Jpn J Clin Oncol*; 34: 148-190.
- Kittlesen DJ, Chianese-. et al. (2000):** Interaction between complement receptor gClqR and hepatitis C virus core

protein inhibits T-lymphocyte proliferation. / *Clin Invest* 2000; **106**:1239-1249

Koike, Y.; Shiratori, Y.; Sato, S.; et al. (2001): Des-gamma-carboxy prothrombin as a useful predisposing factor for the development of portal venous invasion in patients with hepatocellular carcinoma: a prospective analysis of 227 patients. *Cancer*; *91*:561-569.

Kok KF, Wahab PJ, Houwen. ; et al. (2007): Heterozygous alpha-I antitrypsin deficiency as a co-factor in the development of chronic liver disease: a review. *Neth J Med* 2007; *65*:160-166

Kotoh, K.; Sakai, H.; Sakamoto, S.; et al. (1994): The effect of percutaneous ethanol injection therapy on small solitary hepatocellular carcinoma is comparable to that of hepatectomy. *Am J Gastroenterol*; *89*: 194-198.

Kouroumalis, E.; Skordilis, P.; Thermos, K.; et al. (1998): Treatment of hepatocellular carcinoma with octreotide: a randomized controlled study. *Gut*; *42*: 442-447

Kubo, S.; Nishiguchi, S.; Hirohashi, K.; et al. (2002): Randomized clinical trial of long-term outcome after resection of hepatitis C-related hepatocellular carcinoma by postoperative interferon therapy. *Br J Surg*; *89*: 418-422.

Kubota, K.; Hisa, N.; Fujiwara, Y.; et al. (2000): Evaluation of the intratumoral vasculature of hepatocellular carcinoma and adenomatous hyperplasia with power Doppler sonography: advantages and disadvantages versus

- conventional color Doppler sonography. *Abdom Imaging*; 25: 172-178.
- Kudo, M. (1997):** Ultrasound. In: Liver Cancer. Okuda, K. and Tabor, E. (eds), 1st edition, Churchill Livingstone, New York, Edinburgh, London, Melbourne, Sanfranciso, Tokyo, p: 331-346.
- Kudo, M. (1999):** Imaging diagnosis of HCC and premalignant/ borderline lesions. *Semin Liver Dis*; 19: 291.
- Kudo, M. and Okanoue, T. (2007):** Management of hepatocellular carcinoma carcinoma in Japan: Consensus-based clinical practice manual proposed by the Japan society of Hepatology. *Oncology*; 72: 2-15.
- Kudo, M.; Chung, H. and Bruix, J. (2003):** Prognostic staging system for hepatocellular carcinoma (CLIP): its value and limitations and a proposal for a new staging system, the Japan integrated staging score (JIS score). *J Gastroenterol*; 38: 207-215.
- Kulik, L.M.; Atassi, B.; Holsbeeck, L.V.; et al. (2006):** Yttrium-90 micospheres (TheraSphere®) treatment of unresectable hepatocellular carcinoma: downstaging to resection, RFA and bridge to transplantation. *J. Surg. Oncol*; 94: 572-586.
- Kurokochi, K.; Masaki, T.; Miyauchi, Y.; et al. (2004):** Percutaneous ethanol and lipiodol injection therapy for hepatocellular carcinoma. *International J of Oncology*; 24: 381-387.

- Kurokochi, K.; Watanabe, S.; Masaki, T.; et al. (2002):** Combined use of percutaneous ethanol injection and radiofrequency ablation for effective treatment of hepatocellular carcinoma. *Int J Oncol*; 21(4): 841-846.
- Kuzuya, T.; Katano, Y.; Kumada, T.; et al. (2006):** Efficacy of antiviral therapy with lamivudine after initial treatment for hepatitis B virus-related hepatocellular carcinoma. *J of Gastroenterology and Hepatology*; 1440 (Abstract).
- Lagiou P, Kuper H.; et al. (2000):** Role of diabetes mellitus in the etiology of hepatocellular carcinoma. / *Nail Cancer Inst* 2000; **92**: 1096-1099
- Lau, W.Y.; Leung, T.W.; Ho, S.K.; et al. (1999):** Adjuvant intra-arterial iodine-131-labelled lipiodol for resectable hepatocellular carcinoma: prospective randomised trail. *Lancet*; 353: 797-801.
- Lau, W.Y.; Leung, T.W.; Yu, S.C.; et al. (2003):** Percutaneous local ablative therapy for hepatocellular carcinoma. A Review and look into the future. *Annals of Surgery*; 237 : 171-179.
- Lawrence, S.P. (1996):** Evaluation of focal liver masses. In Me Nally PR (ed) *GI/Liver secrets. Hanley and Belfus; Philadelphia: 148-157.*
- Lencioni, R.; Caramella, D. and Bartolozzi, C.; et al. (1995):** Hepatocellular carcinoma: Use of color Doppler US to evaluate response to treatment with percutaneous ethanol injection. *Radiology*; 194. 113-118.

- Lencioni, R.; Caramella, D.; Vingali, C.; et al. (1994):** Lipiodol CT in the detection of tumour persistence in hepatocellular carcinoma treated with percutaneous ethanol injection. *Aceta Radiol*; 35: 323.
- Lerat H, Hollinger FB.(2004):** Hepatitis C virus (HCV) occult infection or occult HCV RNA detection? *J Infect Dis*; 189:
- Leung, T.W.; Tang, A.M.; Zee, B.; Lau, W.Y.; et al. (2002):** Construction of the Chinese University Prognostic Index for hepatocellular carcinoma and comparison with the TNM staging system, the Okuda staging system, and the Cancer of the Liver Italian Program staging system: a study based on 926 patients. *Cancer*; 94: 1760-1769.
- Leung, Tw.; and Johson , PJ. (2001) :** Systemic Therapy for HCC. Semin . in Oncol ., 28(5) : 514 – 520 . liver transpl., 12 (11 suppl 2) : S1 – S7 .
- Levrero M. (2006):** Viral hepatitis and liver cancer: the case of hepatitis C. *Oncogene* 2006; 25: 3834-3847
- Levy, I. and Sherman, M. (2002):** Staging of hepatocellular carcinoma: Assessment of CLIP, Okuda, and Child-Pugh staging systems in a cohort of 257 patients in Toronto. *Gut*; 50: 881-885.
- Lewis, D.R.; Southwick, J.W.; Ouellent-Hellstrom, R.; et al. (1999):** Drinking water and arsenic in Utah: a cohort mortality study. *Environ Health respect*; 107:359-365.

- Lin, X.D. and Lin, L.W. (2006):** Local injection therapy for hepatocellular carcinoma. *Hepatobiliary Pancreat Dis Int*; 5: 16-21.
- Liovet, J.M.; Fuster, J. and Bruix, J. (2004):** The Barcelona approach: diagnosis, staging, and treatment of hepatocellular carcinoma. *Liver Transplantation*; 10(2): suppl 1: S115-S120.
- Liu, L.M.; Zhang, Y.H.; Xu, G.Y.; et al. (2000):** A study of the feasibility of sodium hydroxide solution as tumour ablation agent. *Chin J Ultrasound Med*; 16: 325-327.
- Liver Cancer Study Group of Japan (1999):** Survey and follow-up study of primary liver cancer in Japan: Report 13. *Acta Hepatologica Japonica* 40: 288–300.
- Livraghi, T. ; Meoni , F.; Morabito, A. et al. (2004):** Multi modal image – guided tailored therapy of early and intermediate HCC : long – term survival in the experience of a single radiological referral center. *Liver – Transpl. ; 10 (2) : 98 – 106 .*
- Livraghi, T.; Festi, D.; Monti, F.; et al. (1986):** US-guided percutaneous alcohol injection of small hepatic and abdominal tumour. *Radiology*; 161: 309-312.
- Livraghi, T.; Mkuuchi, M.; Buscarini, L.; et al. (1997):** Diagnosis and treatment of hepatocellular carcinoma, 1st edition, *Greenwich Medical Media, London, p339.*
- Llovet, J.M. and Bruix, J. (2008):** Novel advancements in the management of hepatocellular carcinoma in 2008. *J. of Hepatology*; 48: S20-S37.

- Llovet, J.M.; Sala, M.; Castells, L.; et al. (2000):** Randomized controlled trial of interferon treatment for advanced hepatocellular carcinoma. *Hepatology*; 31: 54-58.
- Lok, A.S. (2004):** Prevention of hepatitis B virus-related hepatocellular carcinoma. *Gastroenterology*; 127: S303-S309.
- Lonardo A, Adinolfi LE, Petta S et al.(2009):** Hepatitis C and diabetes: The inevitable coincidence? *Expert Rev Anti Infect Ther* 2009; 7:293-308 .LCrossRefJ[Medlinej
- London WT, McGlynn KA.; et al. (2002):** Cancer epidemiology and prevention. New York, NY: Oxford University Press, 1996: 772-793
- Lopez, J.B. (2005):** Recent development in the first detection of hepatocellular carcinoma. *Clin. Biochem. Rev.*; 26: 65-79.
- Lovett, J.; Bustamane, J.; Castells, A.; et al. (1999):** Natural history of untreated nonsurgical hepatocellular carcinoma: rationale for the design and evaluation of therapeutic trails. *Hepatology*; 29: 62-67.
- M. Nadia, G. Iman, A. Iman,(2007):** Cancer Pathology Registry: 2003–2004, and Time Trend Analysis, National Cancer Institute, Cairo University,
- M.M. Hassan, A.S. Zaghloul, H.B. El-Serag; et al. (2001):** The role of hepatitis C in hepatocellular carcinoma: a case control study among Egyptian patients, *J. Clin. Gastroenterol.* 33 (2) 123–126.

- Makuuchi, M.; Kokudo, N.; Arii, S.; et al. (2008):** Development of evidence-based clinical guidelines for the diagnosis and treatment of hepatocellular carcinoma. *Hepatology research*; 38: 37-51.
- Makuuchi, M.; Liver Cancer Study Group of Japan, (2000):** The general rules for the clinical and pathological study primary liver cancer (in Japanese). 4th ed. Tokyo: Kanehara and Co; p.19.
- Malaguamera, M.; Di Fazio, I.; Laurino, A.; et al. (1996):** Role of interleukin-6 in hepatocellular carcinoma. *Bull Cancer*; 83: 379-384.
- March , Momenti E., Dvorchik 1 et al. (1999):** Primary hepatic neoplasms. *Swg . elini . H.Am.*, 79 : 43 – 57 .
- Marrero, J.A.; Baneggura, A.; Fu, S.; et al. (2003):** Smoking, Obesity and alcohol are important risk factors in American patients with HCC: a case control study. *Hepatology*; 38: 278A.
- Marrero, J.A.; Fontana, R.J.; Barrat, A. et al. (2005):** Prognosis of hepatocellular carcinoma: comparison of 7 staging systems in an American cohort. *Hepatology*; 41: 707-716.
- Martins, A.; Cortez-Pinto, H.; Marques-Vidal, P.; et al. (2006):** Treatment and prognostic factors in patients with hepatocellular carcinoma. *Liver International*; 26: 680-687.
- Martinz-Maza, O. and Breek, J.S. (1991):** Interleukin-6 and cancer treatment. *In Vivo*; 5: 583-588.

- Mason, A.L.; Lau, J.Y.; Hoang, N.; et al. (1999):** Association of diabetes mellitus and chronic hepatitis C virus infection. *Hepatology*; 29: 328- 333.
- Masuzaki, R. and Omata, M. (2008):** Treatment of hepatocellular carcinoma. *Indian J Gastroenterol*; 27: 113-122.
- Mazzaferro, V.; Regalia, E.; Doci, R.; et al. (1996):** Liver transplantation for treatment for small hepatocellular carcinoma in patients with cirrhosis. *N Engl J Med*; 334: 393-399.
- McGahan J.P.; Browning, P.D.; Brock, J.M.; et al. (1990):** Hepatic ablation using radiofrequency electrocautery. *Invest Radiol*; 25: 267.
- McGlynn, K.A. and London, W.T. (2005):** Epidemiology and natural history of hepatocellular carcinoma. *Best Practice & Research Clinical Gastroenterology*; 19(1): 3-23.
- Mericanc, I.; Guan, R.; Amarapuka, D.; et al. (2000):** Chronic hepatitis B virus infection in Asian countries. *J Gastroenterol Hepatol*; 15: 1356-1361.
- Minagawa, M.; Ikai, IMatsuyama, Y.; et al. (2007):** Staging of hepatocellular carcinoma: Assessment of the Japanese TNM and AJCC/UICC TNM systems in a cohort of 13,772 patients in Japan. *Annals of surgery*; 245: 909-921.
- Minta, M.; Nishida, N.; Komeda, T.; et al. (2001):** Postoperative detection of alpha-fetoprotein mRNA in blood as a

- predictor for metastatic recurrence of hepatocellular carcinoma. *J Gastroenterology Hepatol*; 16: 445-451.
- Mitsuhashi N, Shimizu H, Ohtsuka M, Wakabayashi Y, (2003): Angiopoietins and Tie-2 expression in angiogenesis and proliferation of human hepatocellular carcinoma. *Hepatology* 37:1105-1113 H
- Miyoshi Y, Iwao K, Nagasawa Y, Aihara T, Nakamura Y. (1998):** Activation of the beta-catenin gene in primary hepatocellular carcinomas by somatic alterations involving exon 3. *Cancer Res*; 58: 2524-2527 JS
- Mohamed, N.H.; El-Zawahry, H.; Mokhtar, N.M.; et al.(2000):** Review of epidemiologic and clinicopathologic features of 403 hepatocellular carcinoma. *Journal of the Egyptian cancer National Institute*; 12(2): 87-93.
- Mohr, L. (2007):** Hepatocellular carcinoma: novel therapeutic approaches. *Schweiz Rundsch Med Prax*; 96: 553-562 (Abstract).
- Montello, G.; Cervello, M.; Giannitrapani, L.; et al. (2002):** Epidemiology, risk factors, and natural history of hepatocellular carcinoma. *Ann Acad Scai*; 963: 13-20.
- Moore MA, .; et al. (1998):** Implications of the hyperin-sulinaemia-diabetes-cancer link for preventive efforts. *Eur J Cancer Prev* 1998; 7: 89-107
- Moradpour D, Blum HE. (2005):** Pathogenesis of hepatocellular carcinoma. *Eur J Gastroenterol Hepatol*; 17: 477-483
- Moradpour D, Wands JR. (2002):** Molecular pathogenesis of hepatocellular carcinoma. Philadelphia: W B

Saunders, :1333-1354 9

Nagano, H.; Miyamoto, A.; Wada, H.; et al. (2007): Interferon- α and 5-fluorouracil combination therapy after palliative hepatic resection in patients with advanced hepatocellular carcinoma, portal venous tumour thrombus in the major trunk, and multiple nodules. *Cancer; 110: 2493-2501.*

Nair, S.; Mason, A.; Eason, J.; et al. (2002): Is obesity an independent risk factor for hepatocellular carcinoma in cirrhosis *Hepatology; 36: 150-155.*

Nakashima, T. and Kojiro, M. (1987): Hepatocellular carcinoma. *An Atlas of its pathology. Tokyo: Springer.*

Nakatsura, T.; Yoshitake, Y.; Senju, S.; et al. (2003): Glypican-3, overexpressed specificity in human hepatocellular carcinoma is a novel tumour marker. *Biochem Biophys Res Commun; 306: 16-25.*

Nanashima, A.; Sumida, S.; Tanaka, S.; et al. (2004): The Japanese integrated staging score using liver damage grade for hepatocellular carcinoma in patients after hepatectomy. *EJSO; 30: 765-770.*

Napoli, J.; Bishop and G.A., McCaoghan, G.W. (1994): Increased intrahepatic messenger RNA expression of interleukins 2, 6, and 8 in human cirrhosis. *Gastroenterology; 107: 789-798.*

National Cancer Registry NCR, (2002) : News Letter .

Nelly, H.M.; Heba, M.E.; Samir, S. F.; et al. (2000): Review of epidemiologic and clinicopathologic features of 403

- hepatocellular carcinoma patients. *J Egypt Nat Cancer Inst; 12(2): 87-93.*
- Ng, I.O.; Guan, X.Y.; Poon, R.T.; Fan, S.T.; et al. (2003):** Determination of the molecular relationship between multiple tumour nodules in hepatocellular carcinoma differentiates multicentric origin from intrahepatic metastasis. *J Pathol; 199: 345-353.*
- Nguyen M.H.; Garcia, R.T.; Simpson, P. W.; et al. (2002):** Racial differences of alpha-fetoprotein for diagnosis of hepatocellular carcinoma in hepatitis C virus cirrhosis. *Hepatology; 36: 410-417.*
- O`Neil, B.H. and Venook, A.P. (2007):** Hepatocellular carcinoma: The role of the North American GI Steering Committee Hepatobiliary Task Force and the advent of effective drug therapy. *Oncologist; 12(12): 1425-1432.*
- Ohnishi, K.; Ohyama, N.; Ito, S. and Fujiwara, K. (1994):** Ultrasound guided intratumoral injection of acetic acid for the treatment of small hepatocellular carcinoma. *Radiology; 193: 747-52.*
- Ohnishi, K.; Yoshioka, H.; Ito, S.; et al. (1998):** Prospective randomized controlled trial comparing percutaneous acetic acid injection and percutaneous ethanol injection for small hepatocellular carcinoma. *Hepatology; 27: 67-72.*
- Oka H.; Satio, A.; Ito, K.; Kumada, T.; et al. (2001):** Multicenter prospective analysis of newly diagnosed hepatocellular carcinoma with respect to the percentage of Lens

- culinaris agglutinin-reactive alpha-fetoprotein. *J Gastroenterology Hepatol*; 16: 1378-1383.
- Okazaki, N.; Yoshino, M.; Yoshida, T.; et al. (1989):** Evaluation of the prognosis for small hepatocellular carcinoma on tumour volume doubling time. A preliminary report. *Cancer*; 63: 2207-2210.
- Okuda, H.; Nakanishi, T.; Takatsu, K.; et al. (2000):** Serum levels of des-gamma-carboxy prothrombin measured using the revised enzyme immunoassay kit with increased sensitivity in relation to clinicopathologic features of solitary hepatocellular carcinoma. *Cancer*; 88: 544-549.
- Okuda, H.; Nakanishi, T.; Takatsu, K.; et al. (2001):** Comparison of clinicopathological features of patients with hepatocellular carcinoma seropositive for α -fetoprotein alone and those seropositive for des- γ -carboxy prothrombin alone. *J. Gastroenterol and Hepatol*; 16(11): 1290-1296
- Okuda, K. (2002):** Clinical history of hepatocellular carcinoma including fibrolamellar and hepato-cholangiocarcinoma variants. *J. of Gastroenterology and Hepatology*; 17: 401-405.
- Okuda, K.; Kondo, Y.; Nakano, M.; et al. (1991):** Hepatocellular carcinoma presenting with pyrexia and leukocytosis: report of five cases. *Hepatology*; 13: 695-700.
- Okuda, K.; Noguchi, T.; Kubo, Y.; et al. (1981):** A clinical and pathological study of diffuse type hepatocellular carcinoma. *Liver*; 1: 280-289.

- Okuda, K.; Ohtsuki, T.; Obata, H.; et al. (1985):** Natural history of HCC and prognosis in relation to treatment. Study of 850 patients. *Cancer*; 56: 918-928.
- Okusaka, T.; Okuda, S.; Ueno, H.; et al. (2002):** Satellite lesions in patients with small hepatocellular carcinoma with reference to clinicopathologic feature. *Cancer*; 95: 1931-1937.
- Olweny, C.L. (1984):** Aetiology of hepatocellular carcinoma in Africa. *IARC Press*; 63: 89-95.
- Omagari, K.; Honda, S.; Kadokawa, Y.; et al. (2004):** Preliminary analysis of a newly proposed prognostic scoring system (SLiDe) for hepatocellular carcinoma. *J of Gastroenterology and Hepatology*; 19: 805-811.
- Orlacchio, A.; Bazzocchi, G.; Pastorelli, D.; et al. (2007):** Percutaneous cryoablation of small hepatocellular carcinoma with US guidance and CT monitoring: initial experience. *Cardiovas Intervent Radiol*; 270: 9293-9.
- Ozturk M. (1999):** Genetic aspects of hepatocellular carcinogenesis.
- Parasole, R.; Izzo, F.; Perrone, F. et al. (2001):** Prognostic value of serum biological markers in patients with hepatocellular carcinoma. *Clinical Cancer Research*; 7: 3504-9.
- Park JS, Yang JM, .; et al. (2002):** Hepatitis C virus nonstructural protein NS4B transforms NIH3T3 cells in cooperation with the Ha-ras oncogene. *Biochem Biophys Res Commun* 2002; 267:

- Parkin DM. (2006):** The global health burden of infection-associated cancers in the year. *Int J Cancer* 2006;118:3030-3044JCrpssRefJImedlineJ
- Parkin DM., Muir CS., Whelan SL., et al (1997) :** Cancer incidence in five countries. France : International agency research on cancer
- Paul, S. B.; Gulati, M.S.; Sreenivas, V.; et al. (2007):** Evaluating patients with cirrhosis for hepatocellular carcinoma: Value of clinical symptomatology, imaging and alpha-fetoprotein. *Oncology*; 72(suppl 1): 117-123.
- Perrone, F.; Gallo,C.; Daniele, B.; et al. (2002):** On behalf of the Cancer of the Liver Italian Program (CLIP) investigators. Tamoxifen in the treatment of hepatocellular carcinoma: 5-year results of CLIP-1 multicenter randomized controlled trail. *Current Pharm Design*; 8: 1013-1019.
- Petrides, A.S. and DeFronzo, R.A. (1989):** Glucose and insulin metabolism in cirrhosis. *J Hepatol* 1989; 8: 107-114.
- Pinna, A.D.; Iwatsuki, S.; Lee, R.G.; et al. (1997):** Treatment of fibrolamellar hepatoma with subcostal hepatectomy or transplantation. *Hepatology*; 26: 877-883.
- Poon, R.T. (2007):** Liver transplantation for solitary hepatocellular carcinoma less than 3 cm in diameter in Child A cirrhosis. *Dig Dis*; 25: 334-340.
- Poonawala, A.; Nair, S.P. and Thiluvath, P.L. (2000):** Prevalence of obesity and diabetes in patients with cryptogenic

- cirrhosis: a case-control study. *Hepatology*; 32: 689-692.
- Porta, C.; De Amici, M.; Quaglini, S.; et al. (2007):** Circulating interleukin-6 as a tumour marker for hepatocellular carcinoma. *Annals of oncology*; 24: 1-6.
- Portmann, B.C. (2000):** Anatomy of the normal liver: Comprehensive clinical hepatology. O'Grady, J., Lake, J., Howdle, P. 1st (ed): London, Edinburgh, NEW York, Philadelphia, Sydney and Toronto. Chap. 1
- Qin, L.X. and Tang, Z.Y. (2002):** The prognostic significance of clinical and pathological features in hepatocellular carcinoma. *World J Gastroenterol*; 8(2): 193-199.
- R.E. Velazquez, M. Rodriguez, C.A., N.G. Sotorrios, .; et al. (2003):** Prospective analysis of risk factors for hepatocellular carcinoma in patients with liver cirrhosis, *Hepatology* 37 520–527.
- Raedle, J.; Oremek, G.; Roth, W.K.; et al. (1997):** Anti-p53 autoantibodies in hepatitis C virus-infected patients. *Anticancer Res*; 17: 3079-81
- Rapaccini, G.L.; Pomplili, M.; Caturelli, E.; et al. (2004):** Hepatocellular carcinomas <2 cm in diameter complicating cirrhosis: ultrasound and clinical features in 153 consecutive patients. *Liver Int*; 24(2): 124-130
- Ratziu, V.; Bonyhay, L.; Di Martino, V.; et al. (2002):** Survival, liver failure, and hepatocellular carcinoma in obesity-related cryptogenic cirrhosis. *Hepatology*; 35: 1485-1493.

REFERENCES

- Regimbeau, J.M.; Colombat, M.; Mognol, P.; et al. (2004):** Obesity and diabetes as a risk factor for hepatocellular carcinoma. *Liver Transplant; 10: S69-S73.*
- Ren, Y.; Poon, R.T.; Tsui, H.T.; Chen, W.H.; et al. (2003):** Interleukin-8 serum levels in patients with hepatocellular carcinoma: correlations with clinicopathological features and prognosis. *Clin Cancer Res; 9: 5996-6001.*
- Rhim, H. and Dodd, G.D. (1999):** Radiofrequency thermal ablation of liver tumours. *J of Clinical Ultrasound; 27: 221-229.*
- Roayaie, S.; Haim, M.B.; Emre, S.; et al. (2000):** Comparison of surgical outcomes for hepatocellular carcinoma in patients with hepatitis B versus hepatitis c: a western experience. *Ann Surg Oncol; 7: 764-770.*
- Rolfes, D.B. (1987):** Fibrolamellar carcinoma of the liver. *Tokyo: Springer; 137-142.*
- Rosen, C. and Nagorney, D. (1997):** Fibrolamellar and less aggressive hepatocellular carcinomas. Hepatobiliary malignancy: its multidisciplinary management. *Edward Arnold, London, 5th edition: p 203-214.*
- Rossi, S.; Fornari, F.; Pathies, C.; et al. (1990):** Thermal lesions induced by 480 kHz localized current field in guinea pig liver. *Tumor; 76: 54.*
- Ryder, S.D. (2003):** Guidelines for the diagnosis and treatment of hepatocellular carcinoma (HCC) in adults. *Gut; 52 (suppl III): 1-8.*

- Ryu, M.; Shimamura, Y.; Kinoshita, T.; et al. (1997):** Therapeutic results of resection, transcatheter arterial embolization and percutaneous transhepatic ethanol injection in 3225 patients with hepatocellular carcinoma: a retrospective multicenter study. *Jpn J Clin Oncol*-, 27: 251-257.
- S. Ezzat, M. Abdel-Hamid, S.A.; et al. (2005):** Associations of pesticides, HCV, HBV, and hepatocellular carcinoma in Egypt, *Int. J. Hyg. Environ. Health* 208 (5) 329–339.
- Sala, M.; Llovet J.M.; Vilana, R.; et al. (2004):** Initial response to percutaneous ablation predicts survival in patients with hepatocellular carcinoma. *Hepatology*; 40: 1352-1360.
- Sangiovanni A. , Prati GM., Fasani P ., et al . (2006) :** the natural history of compensated cirrhosis due to hepatitis c virus : a 17 – year cohort study of 214 patients . *Hepatology* , 43(6) : 1303 – B 10 .
- Schachshol; G .; Iochs. H. , and Plauth , M . (2000) :** Controlled clinical trials of doxorubicin and tamoxifen versus tamoxifen monotherapy in HCC . *EUR . J . Gastroenterohepatology*., 12 : 281 – 84 .
- Schafer, D.F. and Sorrell, M.F. (1999):** Hepatocellular carcinoma. *Lancet*; 353: 1253- 1257.
- Schatman SN ., De Man RA ., Staker J., et al (1999) :** subcutaneous seeding of HCC after percutaneous needle biopsy . *GUT*, 45(5) : 1208 – 1236.
- Schölmerich, J. and Schacherer, D. (2004):** Diagnostic biopsy for hepatocellular carcinoma in cirrhosis: useful, necessary, dangerous, or academic sport *Gut*; 53:1224-1226.

- Schuster, M.J. and Wu, G.Y. (1997):** Gene therapy for hepatocellular carcinoma: prognosis but many stones unturned! *Gastroenterology*; 112: 656-659.
- Schwartz, M. (2004):** Liver transplantation for hepatocellular carcinoma. *Gastroenterology*; 127(suppl 1): S 268-276.
- Schwartz, M.; Roayaie, S.; and Konstadoulakis, M. (2007):** Strategies for the management of hepatocellular carcinoma. *Nature Clinical Practice Oncology*; 4(7): 424-432.
- Seeff LB, Hoofnagle JH. (2006):** Epidemiology of hepatocellular carcinoma in areas of low hepatitis B and hepatitis C endemicity. *Oncogene*; 25: 3771-3777
- Seki, T.; Wakabayashi, M.; Nakagawa, T.; et al. (1994):** Percutaneous microwave coagulation therapy for patients with small hepatocellular carcinoma: comparison with percutaneous ethanol injection therapy. *Cancer*; 85: 1694-1702.
- Semin Liver Dis* 1999; 19: 235-242 7
- Sheikh MY, Choi J, Qadri I et al.(2008):** Hepatitis C virus infection: Molecular pathways to metabolic syndrome. *Hepatology* 2008;47:2127-2133.[CrossReaiMedlineJ
- Sherif M ., and Ibrahim A. (1997 a) :** cancer registry for metropolitan Cairo Area. In : Profile of Cancer in Egypt. HCI Cairo University.
- Sherif M ., and Ibrahim A. (1997b) :** Alexandria Cancer Registry in 3 years in profile of cancer in Egypt. NCI Cairo University.

- Sherlock, S. and Dooley, J. (eds). (2002):** Diseases of the liver and biliary system. *Eleventh ed., Blackwell Scientific Publications. Hepatology Research; 19(2): 170- 179.*
- Sherman, M.; Peltkian, K.M.; Lee, C.; et al. (1995):** Screening for hepatocellular carcinoma in cirrhotic carriers of hepatitis B virus: incidence and prevalence of hepatocellular carcinoma in a North American population. *Hepatology; 22: 432-438.*
- Shetty . K.; Timmins , K . ; Brensinger , (et al. 2004) :** Liver transplantation for HCC validation of present selection criteria in predicting outcome. *Liver transplant ., 10 (7) : 911 – 918 .*
- Sheu J.C.; Sung, J.L.; Chen, D.S.; et al (1985):** Growth rate of asymptomatic hepatocellular carcinoma and its implications. *Gastroenterology; 89: 311-317.*
- Shiina, S.; Tagawa, K.; Niwa, Y.; et al. (1993):** Percutaneous ethanol injection therapy for hepatocellular carcinoma: results in 146 patients. *AJR Am J Roentgenol; 162: 1023-1028.*
- Shiina, S.; Tagawa, K.; Unuma, T.; et al. (1991):** Percutaneous ethanol injection therapy for hepatocellular carcinoma. A histopathologic study. *Cancer; 68: 1524 –30.*
- Shimada, M.; Hashimoto, E.; Taniai, M.; et al. (2002):** Hepatocellular carcinoma in patients with non-alcoholic steatohepatitis. *J Hepatol; 37: 154- 160.*
- Shintani Y, Fujie H, Miyoshi H et al.(2004):** Hepatitis C virus infection and diabetes: Direct involvement of the virus

in the development of insulin resistance.
Gastroenterology 2004; 126:840-848.
LCrQSsRefJlMedlineJ

Simonetti RS ., Camma C. Fiorella F., et al ., (1991) :
HCC : A worldwide problem and the major factors .
Dig Dis . Sci., 36 (7) : 962 – 972.

Singh, P.; Erickson, R.A.; Mukhopadhyay, P.; et al. (2007): EUS
for detection of the hepatocellular carcinoma: results of
a prospective study. *Gastrointestinal Endoscopy*; 66:
265-273.

Slama, H. (2003): High intensity focused ultrasound (HIFU), *ESTT*
(*Egyptian Society of Thermo-Therapy*), *second annual*
congress.

Snow berger N ., Chinnakotla S ., Lepe RM., et al . (2007) :
Alpha Fetoprotein , US, C.T and MRI imaging for
detection of HCC in patients with advanced cirrhosis .
Aliment. Pharmacological . Therapy. , 2 (9) : 1187 –
1194 .

Soe, K.L.; Soe, M. and Gluud, C.N. (1992): Liver pathology
associated with the use of anabolic-androgenic steroids.
Liver; 12: 73-79.

Sofocleous, C.T.; Nascimento, R.G.; Gonen, M.; et al. (2007):
Radiofrequency ablation in the management of liver
metastases from breast cancer. *AJR* 189; 883-889.

Soresi, M.; Magliarisi, C.; Sesti, R.; et al. (2003): Usefulness of
alpha-fetoprotein in the diagnosis of hepatocellular
carcinoma. *Anticancer Res*; 23: 1747-1753.

- Spitz, F.R.; Bouvet, M. and Yahanda, A.M. (1999):** Hepatocellular cancers. In Feig. B.W., Berger, D. H., Fuhrman, G.M. (eds) *The MD Anderson Surgical Oncology Handbook*, Second ed, *Lippincott Williams and Wilkins*; pp 223-225.
- Strickland GT. (2006):** Liver disease in Egypt: hepatitis C superseded schistosomiasis as a result of iatrogenic and biological factors. *Hepatology*; 43: 915-922
- Stuart, K.E.; Anand, A.J.; Jenkins, R.I.; et al. (1996):** Hepatocellular carcinoma in the united states. Prognostic features, treatment out-comes, and survival. *Cancer*; 77: 2217-2222.
- Sugawara, Y.; Tamura, S. and Makuuchi, M. (2007):** Living donor liver transplantation for hepatocellular carcinoma: Tokyo university series. *Dig Dis*; 25: 310-312.
- Sugimachi, K.; Tanaka, S.; Terashi, T.; et al. (2002):** The mechanisms of angiogenesis in hepatocellular carcinoma: angiogenic switch during tumour progression. *Surgery*; 16: S135-S141.
- Sugiura, N.; Takara, K.; Phato, M.; et al. (1983):** Percutaneous intratumoral injection of ethanol under ultrasound imaging for treatment of small hepatocellular carcinoma. *Aceta Hepatol Jpn*; 24: 920-923.
- Sun, H.C.; Tang, Z.Y. and Ma, Z.C. (2000):** The factors affecting the recurrent rate after radical resection of liver cancer. *Zhonghua Gandanwaike Zazhi*; 6: 7-9.

- Sun, H.C.; Zhang, W.; Qin, L.X.; et al. (2007):** Positive serum hepatitis B e antigen is associated with higher risk of early recurrence and poorer survival in patients after curative resection of hepatitis B-related hepatocellular carcinoma. *Journal of hepatology*; 47: 684-690.
- Suzuki, M.; Shiraha, H.; Fujikawa, T.; et al. (2005):** Des-gamma-carboxy prothrombin is a potential autologous growth factor for hepatocellular carcinoma. *J Biol Chem*; 280: 6409-6415.
- Szabo E, Paska C, Kaposi Novak P et al. (2004):** Similarities and differences in hepatitis B and C virus induced hepatocarcinogenesis. *Pathol Oncol Res*; 10:5-11.LmedlineJ
- Tada, T.; Kumada, T.; Toyoda, H.; et al. (2005):** Relationship between lens culinaris agglutinin-reactive α -fetoprotein and pathologic features of hepatocellular carcinoma. *Liver International*; 25: 848-853.
- Taha El Khoby, (2000):** Schistosomiasis in Egypt, *Am. J. Trop. Med. Hyg.* 62
- Takano . s. , Yokosuka O., Imaziki F., et al . (1995) :** incidence of HCC in chronic hepatitis B and C : prospective study of 25 patients. *Hepatology* , 21 C3) : 650 – 55 .
- Takano, S.; Watanabe, Y.; Ohishi, H.; et al. (2000):** Multimodality treatment for patients with hepatocellular carcinoma: a single institution retrospective series. *Eur J Surg Oncol*; 26: 67-72.

- Tanaka, H.; Nouse, K.; Kobashi, H.; et al. (2006):** Surveillance of hepatocellular carcinoma in patients with hepatitis C virus infection may improve patient survival. *Liver International*; 26: 543-551.
- Tanaka, K.; Hirohata, T.; Fukuda, K.; et al. (1995):** Risk factors for hepatocellular carcinoma among Japanese women. *Cancer Causes Control*; 6: 91-98.
- Tanaka, S.; Kitamura, T.; Fujita, M.; et al. (1992):** Differentiation from adenomatous hyperplastic nodule with color Doppler flow imaging. *Radiology*; 182: 161-165.
- Tang, W.; Kokudo, N.; Sugawara, Y.; et al. (2005):** Des-gamma-carboxyprothrombin expression in cancer and/or non-cancer liver tissue: association with survival of patients with respectable hepatocellular carcinoma. *Oncol Rep*; 13: 25-30.
- Tangkijvanich, P.; Anukulkarnkusol, N.; Suwangool, P.; et al (2000):** Clinical characteristics and prognosis of hepatocellular carcinoma: analysis based on serum alpha-fetoprotein levels. *J. Clin Gastroenterology*; 34: 302-308.
- Tangkijvanich, P.; Tosukhowong, P.; Unyongyod, P.; et al. (1999):** Alpha-L-fucosidase as a serum marker of hepatocellular carcinoma in Thailand. *Southeast Asian J Trop Med Public Health*; 30: 110-114.
- Taouli B. and Krinsky GA. (2006) :** Diagnostic imaging of HCC in patients with cirrhosis before liver transplantation

- Tateishi, H.; Oi, H.; Masuda, N.; et al. (1997):** Appraisal of combination treatment for hepatocellular carcinoma: long-term follow-up and lipiodol-percutaneous ethanol injection therapy. *Semin Oncol* ;24 (Suppl.6): 81-90
- Tateishi, R.; Yoshida, H.; Shiina, S. et al. (2005):** Proposal of a new prognostic model for hepatocellular carcinoma: an analysis of 403 patients. *Gut*; 54: 419-425.
- Tellinghuisen TL, Rice CM. (2002):** Interaction between hepatitis C virus proteins and host cell factors. *Curr Opin Microbiol*; 5: 419-427
- Ter Haar, G. (2001):** High intensity ultrasound. *Semin Laparosc Surg*; 8: 77-89.
- Terada T, Ueda K, Nakanuma Y. (1993);** Histopathological and morphometric analysis of atypical adenomatous hyperplasia of human cirrhotic livers. *Virchows Arch A Pathol Anat Histopathol*; 422: 381-388
- Thalheimer, U.; Mela, M.; Patch, D.; et al. (2004):** Targeting portal pressure measurements: a critical reappraisal. *Hepatology*; 39: 286-290.
- Theise, N.D. (1995):** Macroregenerative (dysplastic) nodules and hepatocarcinogenesis; theoretical and clinical considerations. *Semin Liver Dis*; 15: 360-371.
- Trevisani, F.; D’Intino P.E.; MorselliLabate, A.M.; et al. (2001):** Serum alpha-fetoprotein for diagnosis of hepatocellular carcinoma in patients with chronic liver disease: influence of HBsAg and anti-HCV status. *J Hepatol*; 34: 570-575.

- Trevisani, F.; De, N.S.; Rapaccini, G.; et al. (2002):** Semi-annual and annual surveillance of cirrhotic patients for hepatocellular carcinoma: effects on cancer stage and patient survival (Italian experience). *Am J Gastroenterol*; 97: 734-744.
- Trevisani, F.; Magini, G.; Santi, V.; et al. (2007):** Impact of aetiology of cirrhosis on the survival of patients diagnosed with hepatocellular carcinoma during surveillance. *Am J of Gastroenterol*; 102: 1022-1031.
- Trotter, J.F.; Wachs, M.; Everson, G.T.; et al. (2002):** Adult-to-adult transplantation of the right hepatic lobe from a living donor. *N Engl J Med*; 346: 1074-1082.
- Tu Z, Pierce RH, Kurtis J et al.(2010):** Hepatitis C virus core protein subverts the antiviral activities of human Kupffer cells. *Gastroenterology* 2010; 138:305-314.[CrQSsRef}[Med!;ne]
- Tunc, B.; Filik, L.; Filik, I.T. et al. (2004):** Brain metastasis of hepatocellular carcinoma: a case report and review of the literature. *World J. Gastroenterol.*; 10(11): 1688-1689.
- Vauthey, B.J.; Lauwers, G.Y.; Esnaola, N.F. et al. (2002):** Simplified staging for hepatocellular carcinoma. *Journal of Clinical Oncology*; 20(b): 1527-1536.
- Velazquez, R.E.; Rodriguenz, M.; Linares, A.; et al. (2003):** Prospective analysis of risk factors for hepatocellular carcinoma in patients with liver cirrhosis. *Hepatology*; 37: 520-527.

- Verset, G.; Verslype, C.; Reynaert, H.; et al. (2007):** Efficacy of the combination of long-acting release octreotide and tamoxifen in patients with advanced hepatocellular carcinoma: a randomized multicentre phase III study. *British Journal of Cancer*; 97: 582-588.
- Weiderpass, E.; Gridley, G.; Nyren, O.; et al. (2001):** Cause-specific mortality in a cohort of patients with diabetes mellitus: a population-based study in Sweden. *J. Clin Epidemiol*; 54: 802-809.
- Williams , P.L.; Bannister , L. H. I Berry , MM et al . (1987):** USA of monoclonal antibodies for diagnosis and treatment of liver tumors. *Clinical Gastroenterology*, 1 : 115 – 123 .
- Willis G, Bardsley V.; et al. (2005):** Hepatocellular carcinoma and the penetrance of HFE C282Y mutations: a cross sectional study. *BMC Gastroenterol* 2005; 5:17
- Wong, G.L.; Tan, G.; Lai, W.; et al. (2007):** Surveillance programme for hepatocellular carcinoma improves the survival of patients with chronic viral hepatitis. *Liver international* ISSN: 1478-3223.
- Wright, T.L. (2007):** Antiviral therapy and primary and secondary prevention of hepatocellular carcinoma. *Hepatology research*; 37(Suppl. 2): S294-S298.
- Wu, F.; Wang, Z.; Chen, W.; et al. (2001):** Pathological ablated hepatocellular carcinoma with high-intensity focused ultrasound. *Zhonghua Zhong Liu Za Zhi*; 23: 237-239.

- Wu, W.; Yao, D.F.; Gu, L.H.; et al. (2006):** Determination of hepatoma-specific alpha-fetoprotein by a mini-column affinity chromatography method. *Chin J Clin Lab Sci*; 24: 10-12.
- Yamashiki, N.; Seki, T.; Wakabayashi, M.; et al. (1999):** Usefulness of Lens culinaris agglutinin A-reactive fraction of alpha-fetoprotein (AFP-L3) as a marker of distant metastasis from hepatocellular carcinoma. *Oncol Rep*; 6: 1229-1232.
- Yan, P. and Yan, L.N. (2003):** Staging of hepatocellular carcinoma. *Hepatobiliary &Pancreatic Diseases International*; 2: 491-495.
- Yang, G.C.; Yang, G.Y. and Tao L.C. (2004):** Distinguishing well-differentiated hepatocellular carcinoma from benign liver by physical features of fine-needle aspirates *Modern Pathology*; 17: 798-802.
- Yang, Q.; McDonnell, S.M.; Khoury, M.J.; et al. (1998):** Hemochromatosis-associated mortality in the United States from 1979 to 1992: an analysis of multiple-cause mortality. *Intern Med*; 129: 946-953.
- Yano, Y.; Yamashita, F.; Sumie, S.; et al. (2002):** Clinical features of hepatocellular carcinoma seronegative for both HbsAg and anti- HCV antibodies but positive but positive for anti-HBc antibodies in Japan. *Am. J Gastroenterol*; 97: 156-161.
- Yates, S.C.; Hafez, M.; Beld. M.; et al. (1999) :** Hepatocellular carcinoma in Egyptians with and without a history of

- hepatitis B virus infection: association with hepatitis C (HCV) infection but not with HCV RNA level. *Am J Trop Med Hyg*; 60(4): 714-720.
- Yeh CT, Chen TC, Chang ML, Hsu CW .; et al.(2007):** Identification of NV-F virus DNA in hepatocellular carcinoma. *J Med Virol*; 79: 92-96
- Yoshida, H.; Tateishi, H.; Arakawa, Y.; et al. (2004):** Benefit of interferon therapy in hepatocellular carcinoma prevention for individual patients with chronic hepatitis C. *Gut*; 53: 425-430.
- Zakaria, S.; El-Rziky, M.; Fouad.; et al. (2000):** Seroprevalence of viral hepatitis markers in a rural and semirural Egyptian district. *Antiviral Therapy*; 5(1): F12.
- Zhang, B. and Yang, B. (1999):** Combined alpha-fetoprotein testing and ultrasonography as a screening test for primary liver cancer. *J Med Screen*; 6: 108-110.
- Zhou, l.; Liu, J. and Luo, F. (2006):** Serum tumour markers for detection of hepatocellular carcinoma. *World J Gastroenterology*; 28: 1171-1181.